Impact of ruxolitinib in myelofibrosis post allogeneic stem cell transplant: A pilot study

A pilot study, presented at the 2018 ASCO Annual Meeting, analyzed the use of ruxolitinib before versus after allogeneic stem cell transplant for patients with intermediate- and high-risk myelofibrosis.

 Journal of Clinical Oncology (ASCO Abstract)

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.